Viking Therapeutics Stock Today
| VKTX Stock | USD 30.48 0.98 3.32% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Viking Therapeutics is trading at 30.48 as of the 16th of February 2025; that is 3.32 percent increase since the beginning of the trading day. The stock's open price was 29.5. Viking Therapeutics has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of April 2015 | Category Healthcare | Classification Health Care |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company was incorporated in 2012 and is headquartered in San Diego, California. Viking Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 111.57 M outstanding shares of which 23.93 M shares are at this time shorted by private and institutional investors with about 6.84 trading days to cover. More on Viking Therapeutics
Moving together with Viking Stock
Moving against Viking Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Viking Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and President and Director | Brian Lian | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsViking Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Viking Therapeutics' financial leverage. It provides some insight into what part of Viking Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Viking Therapeutics (VKTX) is traded on NASDAQ Exchange in USA. It is located in 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121 and employs 6 people. Viking Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.4 B. Viking Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 111.57 M outstanding shares of which 23.93 M shares are at this time shorted by private and institutional investors with about 6.84 trading days to cover.
Viking Therapeutics currently holds about 155.02 M in cash with (73.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02.
Check Viking Therapeutics Probability Of Bankruptcy
Ownership AllocationViking Therapeutics shows a total of 111.57 Million outstanding shares. The majority of Viking Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Viking Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Viking Therapeutics. Please pay attention to any change in the institutional holdings of Viking Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Viking Ownership Details
Viking Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Susquehanna International Group, Llp | 2024-09-30 | 1.1 M | |
| Alliancebernstein L.p. | 2024-09-30 | 1 M | |
| International Assets Investment Management, Llc | 2024-09-30 | 1 M | |
| Westfield Capital Management Company, L.p. | 2024-09-30 | 930.4 K | |
| Amvescap Plc. | 2024-09-30 | 876.2 K | |
| Hood River Capital Management Llc | 2024-09-30 | 815.7 K | |
| Clearbridge Advisors, Llc | 2024-09-30 | 738.6 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 728.7 K | |
| Viking Global Investors Lp | 2024-09-30 | 721.9 K | |
| Fmr Inc | 2024-09-30 | 16.6 M | |
| Vanguard Group Inc | 2024-09-30 | 10.2 M |
Viking Therapeutics Historical Income Statement
Viking Stock Against Markets
Viking Therapeutics Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Michael Morneau | Vice Administration | Profile | |
| Marianne Mancini | Chief Officer | Profile | |
| Geoffrey Barker | Senior Development | Profile |
Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.